Member Info for Icecool

“You are happy with AS behind the steering wheel and I'm not. Nothing either of us say will change the others views”

Yeah pretty much, ok let’s park this then and see if he gets voted out at the AGM.

Again no one here will complain when AVA6000 gets approved by the FDA.

“ I cannot knock your positivity but it’s impossible for me to ignore what has happened.”

Why do you think this isn’t actually the correct strategy for the LTH. If they can get this approved phase 2 solo and partner at way premiums for the platform than before phase 2, you might find the 19% dilution was a good deal. We don’t know the circumstances data or cost benefit analysis done on future deals rather than doing deals phase 1.

Notrex, if you are worried sell up and stop moaning every day at how you screwed up not selling out at 130 and buying back in at 50p. All you do is moan about Smith and this placing. Move on.

Yeah our NEW European health fund and NEW USA institutional investors (40 day black out) forward sold. True some institutions on the placing took advantage of forward selling on the drop from 130 however it won’t have been all of them, also it wouldn’t have been significant amounts as no TR1s were RNS’d.

“The science “working” is only half the battle, you need the structure and commercial know how to bring it to fruition.”

You don’t think Simon can bring this to fruition and get AVA6000 approved? The short term share price is irrelevant on the above. The institutions invested 26 million at 50p for the longterm commercial success of Avacta, don’t get long term investment opportunities, confused by the short term volatility of the market.

@Morris

Sorry but we have hired a commercial lead for therapeutics. He’s pretty experienced.

“Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America”

Institutional investors don’t pony up 26 million plus on blind faith when the interest rate at the moment is pretty attractive.

“Or to put it another way. If the share price remains at 50 pence when the next instalment is due.”

Why would the price remain at 50p when we are expecting a full update on new clinical data. Find it hilarious that this is still down at 50p in the first place.

1. Avacta confirmed timescales and safety previous RNS

2. The 34% discount (real terms was 50% discount based on the magnet price of 100) has been wiped out on approximately 19% dilution yet we are fully funded and science is improving. Thats not logical imo, based on sentiment not facts.

3. The convertible bond can be paid in cash anytime. No death spiral.

We are heading into the month of April, note in the previous RNS they still have patients dosed in the 3 week study, thats some amount of targeted Dox chemo being administered directly to the tumour site, wonder what the results are going to be.

Shareholders won’t be complaining, when the FDA eventually approves AVA6000.

1. No MTD found.

2. Biopsy data has shown proof of platform mechanism.

3. Dox kills cancer cells (been established since the 1960s)

4. Deemed safe at 3.5 times the normal standard dose of Dox. With no dose limiting side effects.

Remember why you invested in Avacta in the first place. Have a great day. 💯😊👍

I mean the results are still on schedule for the end of Q2 and the start of the phase 2 dose expansion end of year followed by phase 2 efficacy straight after. I am sure the team have everything In hand. Commercialisation is still 2026 happy days.

Think it’s very clear from Avacta they are going to give the FDA as much data as possible probably way over the top for a standard phase 1 trial. You don’t obtain 10 biopsies from 9 different patients in multiple cohorts if all you are looking at is safety in phase 1. I could be totally wrong however don’t think other companies, have done that phase 1.

Biopsy slides bruv 😎. In the meantime chill out.

You are just talking rubbish now…. 🤣🤣👍

“Just because Amazon says my parcel has been delivered it doesn’t mean it will work when I open the box🤣🤣🤣🤣🤣”

Depends what was inside the box, if it was an item that was well understood over a period of 50 odd years that had a track record of doing exactly what you thought time and time again with a great track record let’s say a Staedtler pencil, that’s way less risky than some new technology that no one knows anything about, with many complex parts that could go wrong, let’s say a 10 colour ball point pen with flashing neon lights. 👍😜

Well if the platform works, you are actually questioning whether Dox works, which we know it does, otherwise it wouldn’t be an established chemo drug.

From the RNS.

These emerging data clearly demonstrate that the pre|CISION? peptide drug conjugate platform is functioning in the way it was designed and is capable of targeting the release of a cancer therapy to the tumor.

👍👍

Well going by the Turner note which makes a lot of sense now, having had today’s RNS. The Phase 3 is for international opportunities. It’s clear they want AVA6000 approved by the FDA or the SMDC (back in Britain) Asap then partner at a way better deal. It’s also clear if the SMDC said it’s safe, the FDA will have likely come to the same conclusions and it’s only a matter of time before one of the FDA acceleration programs gets involved. AVA6000 is normal Dox and it is now officially deemed safe at 3.5 times the previous standard dose with no dose limiting toxicity. The bar is very low to replace the standard treatment it’s so toxic, we have passed over that bar imo and it’s inevitable the regulators will catch up imo. Only a matter of time now.

“Cohort 7 was the final cohort in the three-weekly study and even at this dose level (385 mg/m2), which is approximately 3.5x the equivalent standard dose of doxorubicin, dose-limiting toxicities were not observed and the Safety Data Monitoring Committee ("SMDC") has concluded that this dose level is safe. A number of patients remain on the three-weekly study at this time in several different cohorts.”

This could be the most significant paragraph in the entire RNS imo. We already know a cumulative dose of Dox has a significant impact on tumour disruption. The fact is the SMDC has now said 385mg is now “Safe” without observing any cardio-toxicity or dose limiting toxicity is incredible. Chris also mentioned a clear hypothesis of increased dose of Dox and increased efficacy within the FAP rich Tumour environment via the biopsy data. My understanding is 3w dose is only given because the body needs to recover from the toxins involved in chemotherapy. Based on the above paragraph (385mg safe) it’s clear we are going to get very near this level in the 2w study as well, however I think they will already have a optimal dose in mind based on all the data gathered so far. Pretty exciting stuff I expect several new case studies in the April update. It’s clear now in my eye's based on the data released today, they wanted to take this solo and all the way rather than partner up.

Wasn’t talking about you specifically 🙄. Just saying folk need to read the RNS’s to get the simple info that’s already available before trashing the company.

“To me it’s still not worth losing my shirt over”

That’s totally fine 👍👍💯 your opinion.

On a side note Avacta don’t care about the short term action on its share price, they are concentrating on the day job and have said they will give updates on the 3w/2w study late Q2. They have hired commercial expertise and seem to be wanting to go solo rather than partnering up. Dox is a multi billion dollar drug. So 18-20% dilution won’t affect the endgame that much if AVA6000 replaces it, when AVA6000 gets approved either by surrogate endpoint (PFS) or normal phase 2. This will be a total game changer for the company, you can either wait till FDA approval and buy in then or you can understand the research and be an early investor. Doesn’t put me up or down either way but try read the RNS’s first before trashing the company on a BB at least get the basics correct, would appreciate that 💯👍.